High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta). The study will use a usual dose of Risperdal Consta (50 mg given every two weeks) or a higher dose (75 mg-100 mg given every two weeks) to see which one is better at improving symptoms of schizophrenia or schizoaffective disorder.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University; Vanderbilt University Medical Center
• Collaborator: Ortho-McNeil Janssen Scientific Affairs, LLC
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Patients diagnosed with schizophrenia or schizoaffective disorder

• Able to give written informed consent.

• Moderate psychosis persists although compliant with medication

• Patients must have an inadequate response to two antipsychotic medications (can be risperidone, oral or long acting - but not required), at doses that are within the upper end of the standard dosage range

• Patients must have a Clinical Global Impression - Severity (CGI-S) scale score at screening of at least moderate severity and a PSP score of 60 or below.

• At the time of screening, eligible patients will be receiving or have received treatment with risperidone oral or Consta, or a combination that does not exceed 50 mg q 2 weeks of Consta or oral risperidone 8 mg/day for at least 6 weeks within seven years of study entry without satisfactory response as documented in the medical record Risperidone

• Patients who have received Consta injectable medication within the specified dose range for no more than a month prior to the onset of the study will be eligible. Patients receiving mood stabilizers or antidepressants, or both, in addition to risperidone oral or Consta, will be eligible

• Patients may initially be inpatients or outpatients

• Females of child bearing potential will be admitted only if they are on stable birth control medication and understand that they should not get pregnant during the course of the study.

• All patients must have stable housing at the current time or plans for housing following hospital discharge, if an inpatient.

• Patients must be willing to receive injectable medication

Exclusion Criteria:

• Patients with a diagnosis other than schizophrenia or schizoaffective disorder.

• Patients previously treated with doses of these agents higher than those allowed for at least six months and who failed to have an adequate response will be excluded

• Patients currently taking clozapine or have failed an adequate trial of clozapine which lasted at least 3 months

• Pregnant females. Females who are currently breastfeeding will be excluded.

• Patients with a diagnosis of substance dependence at screening or up to one year prior to enrollment.

• Patient with worse than mild tardive dyskinesia or history of marked EPS at screening

• Patients who have had neuroleptic malignant syndrome

• Patients with a history of galactorrhea

• Patients with uncontrolled medical condition(s)

• Patients with a history of non-compliance to oral or injectable medication.

• Patients unwilling to have injectable medication